...

 
Cannvas.Me
Sign Up For Free
  • Post Time Posted August 09, 2018
Health Canada has approved Tetra Bio-Pharma Inc’s protocol for a clinical trial investigating its PPP001 drug as an alternative to fentanyl in the management of breakthrough cancer pain. 

Montreal-based Sante Cannabis, a medical clinic and contract research organization specialized in cannabis-based therapies will conduct the study.

The study will assess the time-to-relief in patients suffering from breakthrough cancer pain. 

Unlike typical medical cannabis, PPP001 is a prescription drug that has a Drug Identification Number (DIN) that makes it much easier to be eligible for insurance coverage.
 
There is a growing movement against the use of opioids due to their highly addictive nature, and many people believe that medical cannabis products and by-products may be able to replace them in some cases. 

Source: https://markets.businessinsider.com/news/stocks/health-canada-gives-green-light-to-tetra-bio-pharma-s-cannabis-vs-fentanyl-trial-1027446396

This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.

Reviews

Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.
Close